Gubra A/S Gross Margin

What does Gubra A/S do? Gubra A/S generates revenue through its CRO Segment, which provides pre-clinical contract research services for metabolic and fibrotic diseases including diabetes, obesity, and chronic kidney disease. These services are delivered at attractive margins using advanced technology platforms incorporating automation, robotization, and digitalization with machine learning and artificial intelligence. The Discovery and Partnership Segment develops peptide-based drug candidates for metabolic and fibrotic diseases through an internal target and drug discovery engine, forming partnerships with pharmaceutical companies seeking drug development opportunities. The company's primary clients are pharmaceutical firms requiring specialized research services and drug discovery solutions within metabolic and fibrotic disease areas. Gubra A/S's business model relies on two distinct revenue streams: the CRO Segment's pre-clinical research services and the Discovery and Partnership Segment's drug discovery engine. The CRO Segment focuses on delivering profitable research services with high margins, while the Discovery and Partnership Segment creates partnership opportunities by identifying and designing peptide-based drug candidates. Both segments target the pharmaceutical industry's need for specialized research and drug development within metabolic and fibrotic disease markets. The company's technology platforms leverage automation, robotization, and digitalization with machine learning and artificial intelligence to enhance service delivery and drug discovery processes. These platforms enable Gubra A/S to provide efficient, high-quality research services and identify promising drug candidates. The primary market segments served are pharmaceutical companies seeking pre-clinical research support and drug discovery solutions for metabolic and fibrotic diseases. Gubra A/S is one of the most popular companies on Eulerpool.